ESPR - CIK 0001434868
The table below shows Esperion Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$13.09M | -$23.65M | -$135.49M | -$174.83M | -$263.81M | -$85.18M |
| Capital expenditure | $0.00 | $317.00K | $0.00 | $0.00 | $0.00 | $869.00K |
| Investing cash flow | $0.00 | -$317.00K | $42.50M | $8.10M | -$50.48M | $21.36M |
| Dividends paid | - | - | - | - | - |
Esperion Therapeutics, Inc. reported operating cash flow of -$13.09M for fiscal year 2025. That is up 44.6% from -$23.65M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$47.73M (FY 2016) to -$13.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | $0.00 | $55.00M |
| Financing cash flow | $36.18M | $86.48M | $50.46M | $32.61M | $268.22M | $201.72M |